This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Autoinjectors To 2018 - Devices, Therapeutics, Markets, Strategies And Prospects

NEW YORK, March 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Autoinjectors to 2018 - Devices, Therapeutics, Markets, Strategies and Prospects

http://www.reportlinker.com/p0850146/Autoinjectors-to-2018---Devices-Therapeutics-Markets-Strategies-and-Prospects.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

While autoinjectors are sometimes designed to work with a particular injectable product as a form of pharmaceutical branding, the typical autoinjector is designed to fit one or more standard sizes of prefilled disposable syringes. Until recently, autoinjectors were designed to be reused. The reason was that the injectors were too expensive to be successfully marketed as a throw-away device. Recent improvements in materials technology and device design have led to the creation of a class of autoinjectors that can be made economically in high production quantities, opening the door for the disposable autoinjector, and providing expanded opportunities for both patient and drug marketer.

Highlights

• Analyzes therapeutic demand drivers and evaluates commercial prefilled syringe products in eleven major therapeutic segments

• Analyzes design factors, material selection issues, technologies and market development issues

• Profiles injectable drug and device participants, their product development activities, business strategies, and corporate alliances and affiliations

• Charts market data and forecasts to 2018

Table of Contents

Executive Summary

Injectable Drug Delivery Market Dynamics

The Economics of Injectable Drugs

What's Driving the Growth in Autoinjectors?

Prefilled Syringes Proliferating

The Trend toward Self-Administration

Shifting Demographics

Innovation in Disposable Device Designs

Therapeutic Demand Drivers

Competitive Landscape

Risk Factors

Autoinjectors – Commercial Devices

Manual injection Autoinjectors

Automated Injection Autoinjectors

Reusable Autoinjectors

Disposable Autoinjectors

Bundled (Pre-assembled) Autoinjectors

Product Specific Autoinjectors

Autoinjector Device Design Factors

Material Selection Issues

Part Counts and Device Cost

Safety Features

Needle Shielding

Needle Insertion Depth

Failsafe Activation

Dose Inspection/Injection Confirmation

Lyophilized Drugs/Reconstitution

Human Engineering/Ergonomics

Autoinjector Drug Delivery – Key Therapeutic Sector Analysis

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs